

SCIENTIFIC PROGRAM

BTG 2016 SCIENTIFIC AGENDA: SESSION DAY 1

SATURDAY, FEBRUARY 27, 2016

8:00 AM-8:30 AM	Inauguration Session Welcome Note APHCON Update	Morton Coleman Juan Li & Robert Orlowski Xiao Jun Huang
8:30 AM-10:00 AM	MULTIPLE MYELOMA - I	Moderators: Kaiyan Liu & Wenming Chen
8:30 AM	The future of antibody therapies and drug conjugates in multiple myeloma (20 min) <i>Robert Orlowski, MD, PhD (MD Anderson Cancer Center, Houston, USA)</i>	
8:50 AM	The optimal induction therapy for newly diagnosed transplant eligible myeloma? (20 min) <i>James Chim, MD, PhD (University of Hong Kong)</i>	
9:10 AM	Is 'Induction-ASCT-Maintenance' the therapy of choice for all patients with newly diagnosed myeloma? (10 min) <i>Juan Li, MD (Sun Yat-Sen University, Guangzhou, China)</i>	
9:20 AM	Debate Session: Should we treat smoldering myeloma? Yes: <i>Jin Lu, MD (Peking University, Beijing, China)</i> (10 min) No: <i>Chepsy Philip, MD (CMC, Ludhiana, India)</i> (10 min)	
9:40 AM	APHCON YOUTH CONGRESS ANNOUNCEMENT	XJ Huang, Surapol Issaragrisil & Simrit Parmar
10:00 AM-10:30 AM	Coffee Break	
10:30 AM-12:00 PM	MULTIPLE MYELOMA - II	Moderators: Daobin Zhou & William Hwang
10:30 AM	MRD Assessment and its application for multiple myeloma (15 min) <i>Jian Hou, MD, PhD (Shanghai Changzheng Hospital, Shanghai, China)</i>	
10:45 AM	Debate Session: What is optimal maintenance therapy duration for a newly diagnosed multiple myeloma patients completing induction, ASCT and consolidation? Maintenance for 2 years only: <i>Nuchanan Areethamsirikul, MD (Siriraj Hospital, Bangkok, Thailand)</i> (10 min) Continuous maintenance therapy: <i>Govind Babu, MD (Kidwai Memorial Institute, Bangalore, India)</i> (10 min)	
11:15 AM	Immunotherapy in Multiple Myeloma <i>Robert Orlowski, MD, PhD (MD Anderson Cancer Center, Houston, USA)</i> (20 min)	
11:45 AM	Q and A	
12:00 PM-2:00 PM	LUNCH SYMPOSIUM	
12:00 – 1:00 PM	CELGENE: MULTIPLE MYELOMA Moderator: Xiaojun Huang, MD, PhD and Kaiyan Liu, MD, PhD - MM ASH 2015 highlights (20 min): <i>Wenming Chen, MD Beijing Chaoyang hospital</i> - Newly diagnosed multiple myeloma treatment updates (20 min): <i>Jim LU, MD Peking University People Hospital</i> - Relapsed/Refractory multiple myeloma treatment updates (20 min): <i>Jian HOU, MD, PhD Shanghai Changzheng hospital</i>	
1:00 PM – 2:00 PM :	SANOFI: GVHD Moderator: Kaiyan Liu, MD, PhD (Peking University, Beijing, China) Speaker: He Huang, MD, PhD (Zhejiang University School of Medicine, Hangzhou, China)	

(30 min)

2:00 PM – 3:00 PM

Low Grade Lymphoma

Moderators: Yongping Song & Daryl Tan

2:00 PM

Debate Session: How should a 63 year old male with advanced stage, intermediate risk MIPI mantle cell be treated outside of a clinical trial?

Chemoimmunotherapy with AutoSCT: *William Hwang, MD (National University Singapore) (10 min)*

Chemotherapy-based therapy without transplant: *Piyanuch Kongtim, MD (Siriraj Hospital, Bangkok, Thailand) (10 min)*

2:20 PM

Debate Session: A 60 year old man with stage I (excised) follicular lymphoma, now NED. How should he be treated?

Observation: *Pankaj Malhotra, MD (PGIMER, Chandigarh) (10 min)*

Radiation therapy, with or without systemic treatment: *Adolfo de la Fuente, MD (MD Anderson cancer Center, Madrid) (10 min)*

2:40 PM

Debate: A 48-year-old woman is diagnosed with mildly symptomatic, low tumor burden, stage IV follicular lymphoma, low risk FLIPI score and desires treatment. What is your recommendation?

R-CHOP or B-R: *Weili Zhao, MD (Shanghai Ruijin Hospital, Shanghai, China) (10 min)*

Single agent rituximab or a combination “biologic doublet” therapy: *Swami Iyer, MD (Houston Methodist Cancer Center, Houston, USA) (10 min)*

3:00 PM – 3:45 PM

B Cell Lymphoma

Moderators: Junmin Li & Nuchanan Areethamsirikul

3:00 PM

Double hit lymphoma. What is it and how should we treat it? (10 min)

Morton Coleman, MD (Cornell University, New York, USA)

3:10 PM

Should we treat patients with DLBCL differently today based on cell of origin (Germinal Center/Non-Germinal Center)?

Yes: *Daryl Tan, MD (Raffles Hospital, Singapore) (10 min)*

No: *Frederick Hagemester, MD (MD Anderson Cancer Center, Houston, USA) (10 min)*

3:30 PM

Upfront autologous transplant in high risk DLBCL. The current guidelines and recommendations (10 min)

Yu Hu, MD, PhD (Huazhong University of Science and Technology, Wuhan, China)

3:50 PM-4:10 PM

Coffee Break

4:10 PM – 5:00 PM

T Cell Lymphoma

Moderators: Qifa Liu & Piyanuch Kongtim

4:10 PM

Current challenges in diagnosis and management of extranodal NK/T cell Lymphoma nasal type (10 min)

Tong Yu Lin, MD (Sun Yat-Sen University, Guangzhou, China)

4:20 PM

Recent treatment for NK/T cell lymphoma: Chinese experience (10 min)

Huiqiang Huang, MD (Sun Yat-Sen University Cancer Center, Guangzhou, China)

4:30 PM

Targeted Therapy for PTCL (15 min)

YL Kwong, MD, PhD (University of Hong Kong)

4:45 PM

Allogeneic transplant for Lymphoma (15 min)

Dharma Choudhary, MD (BLK Hospital, New Delhi)

5:00 PM

ADJOURN

BTG2016 SCIENTIFIC AGENDA: SESSION DAY 2

SUNDAY, FEBRUARY 28, 2016

Time	Events and Topics	Location and Speakers
8:00 AM-8:40 AM	MYELOPROLIFERATIVE DISORDERS	Moderators: Liansheng Zhang & Pankaj Malhotra
8:00 AM	Management of lower-risk MDS without del5q and refractory to ESAs (20 min) <i>Zong Hong Shao, MD (Tianjin Medical University General Hospital, Tianjin, China)</i>	
8:20 AM	IPSS, DIPSS, DIPSS-Plus, MISPS, GIPSS: making sense of the tangled web of prognostic scoring systems in MF (10 min) <i>Raymond Wong, MD (Chinese University, Hong Kong)</i>	
8:30 AM	Should JAK2 inhibitors be used for lower-risk MF, or only on-label (higher-risk)? (10 min) <i>Sharat Damodar, MD (NH Narayana Multi-specialty Clinic, Bangalore, India)</i>	
8:40 AM	Treatment Updates for MDS (20 min) <i>Jie Jin, MD (The First Affiliated Hospital, Zhejiang University College of Medicine, Hangzhou, China)</i>	
9:00 AM – 9:20 AM	KIAN ANG MEMORIAL LECTURE The value of collaborative research in oncology <i>Robert Orlowski, MD, PhD (MD Anderson Cancer Center, Houston, USA)</i>	Moderators: Xiaojun Huang Surapol Issaragrisil
9:20 AM – 10:00 AM	BEST ORAL ABSTRACT PRESENTATION	Moderator: Kaiyan Liu & Simrit Parmar
10:00 AM-10:20 AM	Coffee Break/Poster Viewing	
10:20 AM-11:00 AM	HODGKIN'S LYMPHOMA	Moderators: Ting Liu & Chepsy Philip
10:20 AM	What is the standard of care for limited stage Hodgkin's Lymphoma? (10 min) <i>Daryl Tan, MD (Raffles Hospital, Singapore)</i>	
10:30 AM	Advanced stage Hodgkin disease: recent approaches (15 min) <i>Morton Coleman, MD (Cornell University, New York, USA)</i>	
10:45 AM	Clinical Trials Update: PD-1 Blockade in HL (15 min) <i>Frederick Hagemeister, MD (MD Anderson Cancer Center, Houston, USA)</i>	
11:00 AM-12:00 PM	CHRONIC MYELOID LEUKEMIA	Moderators : Jianmin Wang & Sharat Damodar
11:00 AM	How should chronic-phase CML management be influenced by RT-PCR results at 3 months and beyond? (20 min) <i>Dong Wook Kim, MD (Seoul St. Mary Hospital, Seoul, S. Korea)</i>	
11:20 AM	Who should still be transplanted for CML in 2016? (20 min) <i>David Ritchie, MD, PhD (Royal Melbourne Hospital, Australia)</i>	

11:40 AM
Monitoring Chronic Myeloid Leukemia in the Real World (20 min)
Qian Jiang, MD (Peking University, Beijing, China)

12:00 – 2:00 PM LUNCH SYMPOSIUM

12:00 PM-1:00 PM **AMGEN Lunch Session**
Advances in Proteasome Inhibition in Multiple Myeloma
12:00-12:05 (5 min)
Opening and Welcome
Prof Hou Jian, Shanghai Changzheng Hospital, China
12:05-12:30 (25 min)
The Evolving Role of Proteasome Inhibition in Multiple Myeloma
Dr. Robert Z Orlowski, The University of Texas MD Anderson Cancer Center, US
12:30-12:55 (25 min)
New Strategies in Combination Therapies for Multiple Myeloma in Asia Patients
Dr. Cheng-Shyong Chang, Changhua Christian Hospital, Taiwan
12:55-13:00 (5 min)
Q&A
All

1:00 PM-2:00 PM **XIAN JANSSEN SYMPOSIUM:**
Precision therapy for MDS
Moderator: Juan Li, MD (Sun Yat-Sen University, Guangzhou, China)
Speaker: Zong Hong Shao, MD (Tianjin Medical University General Hospital, Tianjin, China)

2:00 PM – 2:20 PM	CHRONIC LYMPHOCYTIC LEUKEMIA	Moderators: Jianda Hu & Dharma Choudhary
2:00 PM	Debate Session: What is the best frontline regimen for a CLL patient aged 60 who requires therapy? (20 min) Fludarabine-Cytosin-Rituxan: <i>Jian Yong Li, MD (First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, China)</i> Ibrutinib-based treatment without chemotherapy: <i>Pankaj Malhotra, MD (PGIMER, Chandigarh, India)</i>	
2:20 PM – 3:00 PM	ACUTE MYELOID LEUKEMIA	Moderators: Zimin Sun & Young-Ho Lee
2:20 PM	Optimal management of newly diagnosed Elderly AML (15 min) <i>Swami Iyer, MD (Houston Methodist Cancer Center, USA)</i>	
2:35 PM	Novel agents for treatment of AML (15 min) <i>Jian Xiang Wang, MD, PhD (Peking Union of Medical College, Tianjin, China)</i>	
2:50 PM	Upfront allogeneic stem cell transplant for standard risk AML (15 min) <i>Xiao Jun Huang, MD, PhD (Peking university, Beijing, China)</i>	
3:05 PM – 3:40 PM	ACUTE LYMPHOCYTIC LEUKEMIA	Moderators: Jiong Hu & Govind Babu
3:05 PM	Optimal induction for Ph+ ALL (15 min) <i>Depei Wu, MD (First Affiliated hospital of Soochow University, China)</i>	
3:20 PM	Immunotherapy for ALL (20 min) <i>David Ritchie, MD, PhD (Royal Melbourne Hospital, Australia)</i>	
3:40 PM	ADJOURN	